Stuttgart - Delayed Quote EUR

AstraZeneca PLC (ZEG.SG)

Compare
136.50
+1.50
+(1.11%)
As of 4:14:33 PM GMT+1. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
51,206,000.00
45,811,000.00
44,351,000.00
37,417,000.00
26,617,000.00
Cost of Revenue
9,790,000.00
8,268,000.00
12,391,000.00
12,437,000.00
5,299,000.00
Gross Profit
41,416,000.00
37,543,000.00
31,960,000.00
24,980,000.00
21,318,000.00
Operating Expense
30,658,000.00
28,821,000.00
27,448,000.00
25,119,000.00
17,402,000.00
Operating Income
10,758,000.00
8,722,000.00
4,512,000.00
-139,000.00
3,916,000.00
Net Non Operating Interest Income Expense
-1,262,000.00
-1,288,000.00
-1,249,000.00
-1,233,000.00
-1,189,000.00
Pretax Income
7,922,000.00
6,899,000.00
2,501,000.00
-265,000.00
3,916,000.00
Tax Provision
1,422,000.00
938,000.00
-792,000.00
-380,000.00
772,000.00
Net Income Common Stockholders
6,495,000.00
5,955,000.00
3,288,000.00
112,000.00
3,196,000.00
Diluted NI Available to Com Stockholders
6,495,000.00
5,955,000.00
3,288,000.00
112,000.00
3,196,000.00
Basic EPS
4.19
3.84
2.12
0.08
2.44
Diluted EPS
4.15
3.81
2.11
0.08
2.44
Basic Average Shares
1,549,750.00
1,549,000.00
1,548,000.00
1,418,000.00
1,312,000.00
Diluted Average Shares
1,563,500.00
1,562,000.00
1,560,000.00
1,427,000.00
1,313,000.00
Total Operating Income as Reported
9,201,000.00
8,193,000.00
3,757,000.00
1,056,000.00
5,162,000.00
Rent Expense Supplemental
--
301,000.00
268,000.00
262,000.00
228,000.00
Total Expenses
40,448,000.00
37,089,000.00
39,839,000.00
37,556,000.00
22,701,000.00
Net Income from Continuing & Discontinued Operation
6,495,000.00
5,955,000.00
3,288,000.00
112,000.00
3,196,000.00
Normalized Income
7,739,698.31
6,375,540.00
3,888,210.00
-852,710.00
2,192,424.92
Interest Income
459,000.00
301,000.00
81,000.00
43,000.00
83,000.00
Interest Expense
1,721,000.00
1,589,000.00
1,330,000.00
1,276,000.00
1,272,000.00
Net Interest Income
-1,262,000.00
-1,288,000.00
-1,249,000.00
-1,233,000.00
-1,189,000.00
EBIT
9,643,000.00
8,488,000.00
3,831,000.00
1,011,000.00
5,188,000.00
EBITDA
14,868,000.00
13,422,000.00
9,085,000.00
5,113,000.00
8,084,000.00
Reconciled Cost of Revenue
9,790,000.00
8,268,000.00
12,391,000.00
12,437,000.00
5,299,000.00
Reconciled Depreciation
5,225,000.00
4,934,000.00
5,254,000.00
4,102,000.00
2,896,000.00
Net Income from Continuing Operation Net Minority Interest
6,495,000.00
5,955,000.00
3,288,000.00
112,000.00
3,196,000.00
Total Unusual Items Excluding Goodwill
-1,517,000.00
-489,000.00
-741,000.00
1,191,000.00
1,250,000.00
Total Unusual Items
-1,517,000.00
-489,000.00
-741,000.00
1,191,000.00
1,250,000.00
Normalized EBITDA
16,385,000.00
13,911,000.00
9,826,000.00
3,922,000.00
6,834,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-272,301.69
-68,460.00
-140,790.00
226,290.00
246,424.92
12/31/2020 - 12/28/2007

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

LLY.DU Eli Lilly and Co
790.90
+0.53%
 
RHO6.SG Roche Holding AG
37.24
-0.02%
 
AMG.DE Amgen Inc.
274.70
+1.22%
 
RHO6.BE Roche Holding AG
37.80
0.00%
 
LLY.MU Eli Lilly and Co
791.10
+2.42%
 
RHHBF Roche Holding AG
331.66
0.00%
 
NOVN.SW Novartis AG
95.58
+1.90%
 
NOV.DE Novo Nordisk A/S
81.62
+0.25%
 
NVS Novartis AG
104.77
+0.02%
 
BIIB Biogen Inc.
144.51
-1.18%